Publications by authors named "Paolo A Ascierto"

100Publications

Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma: A Review.

JAMA Oncol 2020 Sep 24. Epub 2020 Sep 24.

University Hospital Essen, Essen, Germany, and German Cancer Consortium, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2020.4401DOI Listing
September 2020

Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer.

J Clin Oncol 2020 Sep 8:JCO1903205. Epub 2020 Sep 8.

INSERM, Laboratory of Integrative Cancer Immunology, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.03205DOI Listing
September 2020

Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design.

Future Oncol 2020 Jul 29. Epub 2020 Jul 29.

Melanoma Institute Australia, The University of Sydney, Royal North Shore & Mater Hospital, St Leonards, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2020-0351DOI Listing
July 2020

Covid-19: Time for a paradigm change.

Rev Med Virol 2020 09 3;30(5):e2134. Epub 2020 Jul 3.

Institute of Human Virology, Baltimore, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/rmv.2134DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361272PMC
September 2020

Melanoma immunotherapy: strategies to overcome pharmacological resistance.

Expert Rev Anticancer Ther 2020 Apr 6;20(4):289-304. Epub 2020 Apr 6.

Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2020.1745634DOI Listing
April 2020

Multiplex immunohistochemistry assay to evaluate the melanoma tumor microenvironment.

Methods Enzymol 2020 22;635:21-31. Epub 2019 Aug 22.

Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Napoli, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.mie.2019.07.045DOI Listing
August 2019

Biology confirmed but biomarkers elusive in melanoma immunotherapy.

Nat Rev Clin Oncol 2020 04;17(4):198-199

Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Naples, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-020-0328-8DOI Listing
April 2020

Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management.

Melanoma Manag 2019 Nov 8;6(4):MMT30. Epub 2019 Nov 8.

Unit of Melanoma, Cancer Immunotherapy & Innovative Therapies Unit - Istituto Nazionale Tumori Fondazione 'G. Pascale,' IRCCS, 80131, Napoli, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/mmt-2019-0005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6920742PMC
November 2019

Melanoma: Prognostic Factors and Factors Predictive of Response to Therapy.

Curr Med Chem 2020 ;27(17):2792-2813

Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Cancer Immunotherapy and Innovative Therapy Unit, Naples, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/0929867326666191205160007DOI Listing
August 2020

Enzyme activity of circulating CD73 in human serum.

Methods Enzymol 2019 17;629:257-267. Epub 2019 Jun 17.

Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.mie.2019.05.044DOI Listing
June 2020

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

N Engl J Med 2019 10 28;381(16):1535-1546. Epub 2019 Sep 28.

From the Royal Marsden NHS Foundation Trust, London (J.L.), and the College of Medicine, Swansea University, Swansea (J.W.) - both in the United Kingdom; the Oncology Institute of Veneto IRCCS, Padua (V.C.-S.), the European Institute of Oncology, IRCCS, Milan (P.F.F.), Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples (P.A.A.), the Immunotherapy and Somatic Cell Therapy Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (M.G.), and the Center for Immuno-Oncology, Medical Oncology and Immunotherapy, University Hospital, Siena (M.M.) - all in Italy; the University of Colorado Cancer Center, Aurora (R.G.); Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille Hôpital Timone, Marseille (J.-J.G.), and Université de Paris, INSERM Unité 976, Assistance Publique-Hôpitaux de Paris Dermatology and Centres d'Investigation Clinique, Saint Louis Hospital, Paris (C.L.) - both in France; the Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); the University of Michigan, Ann Arbor (C.D.L.); Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas (C.L.C.); the Department of Dermatology, University of Essen, Essen, and the German Cancer Consortium, Heidelberg - both in Germany (D.S.); Universitäts Spital, Zurich, Switzerland (R.D.); Cross Cancer Institute, Edmonton, AB (M.S.), and the Princess Margaret Cancer Centre, Toronto (D.H.) - both in Canada; Tasman Oncology Research, Southport, QLD (A.H.), the Crown Princess Mary Cancer Centre, Melanoma Institute Australia, University of Sydney, Sydney, NSW (M.S.C., G.V.L.), and the Royal North Shore and Mater Hospitals (G.V.L.), Sydney, and the Peter MacCallum Cancer Centre, Melbourne, VIC (G.M.) - all in Australia; General University Hospital Gregorio Marañon and Centro de Investigación Biomédica en Red de Oncología, Madrid (I.M.-R.); the Netherlands Cancer Institute, Amsterdam (J.H.); the Leuven Cancer Institute, Department of General Medical Oncology, University Hospital Leuven, Leuven, Belgium (P.S.); University of California San Diego Health-La Jolla Moores Cancer Center, La Jolla (G.A.D.); the Department of Oncology, Odense University Hospital, Odense, Denmark (L.B.); Bristol-Myers Squibb, Princeton, NJ (J.I.R., A.B., A.M.); Dana-Farber Cancer Institute, Boston (F.S.H.); and the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (J.D.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1910836DOI Listing
October 2019

The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018.

J Immunother Cancer 2019 08 15;7(1):221. Epub 2019 Aug 15.

Department of Medicine, Roswell Park Comprehensive Cancer Center, Developmental Therapeutics, Buffalo, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0683-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6696687PMC
August 2019

The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era.

Curr Oncol Rep 2019 07 29;21(9):76. Epub 2019 Jul 29.

Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Via Mariano Semmola snc, Naples, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0827-xDOI Listing
July 2019

Preanalytic Variables and Tissue Stewardship for Reliable Next-Generation Sequencing (NGS) Clinical Analysis.

J Mol Diagn 2019 09 25;21(5):756-767. Epub 2019 Jun 25.

University of Vermont Health Network, Larner College of Medicine at the University of Vermont, Burlington, Vermont.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmoldx.2019.05.004DOI Listing
September 2019

Frontline Therapy for -Mutated Metastatic Melanoma: How Do You Choose, and Is There One Correct Answer?

Am Soc Clin Oncol Educ Book 2019 Jan 17;39:564-571. Epub 2019 May 17.

4 Massachusetts General Hospital Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_243071DOI Listing
January 2019

The great debate at "Melanoma Bridge 2018", Naples, December 1st, 2018.

J Transl Med 2019 05 10;17(1):148. Epub 2019 May 10.

Clinical Trials Unit, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Naples, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12967-019-1892-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509811PMC
May 2019

Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations.

Expert Rev Clin Pharmacol 2019 Mar 24;12(3):259-266. Epub 2019 Jan 24.

a Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics , Istituto Nazionale Tumori IRCCS Fondazione G. Pascale , Napoli , Italy.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17512433.2019.1
Publisher Site
http://dx.doi.org/10.1080/17512433.2019.1570847DOI Listing
March 2019

Emerging Strategies in Systemic Therapy for the Treatment of Melanoma.

Am Soc Clin Oncol Educ Book 2018 May;38:751-758

From the Istituto Nazionale Tumori "Fondazione G. Pascale," Naples, Italy; Massachusetts General Hospital Cancer Center, Boston, MA; Center for Cancer Research, National Cancer Institute, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_199047DOI Listing
May 2018

Immunological effects of BRAF+MEK inhibition.

Oncoimmunology 2018 23;7(9):e1468955. Epub 2018 Jul 23.

Department of Dermatology, University Hospital Zürich Skin Cancer Center, Zürich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2018.1468955DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140547PMC
July 2018

Anti-PD-1 and PD-L1 antibodies in metastatic melanoma.

Melanoma Manag 2017 Dec 21;4(4):175-178. Epub 2017 Nov 21.

Melanoma, Cancer Immunotherapy & Innovative Therapy Department at National Cancer Institute of Naples, Naples 80131, Italy.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/mmt-2017-0018
Publisher Site
http://dx.doi.org/10.2217/mmt-2017-0018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094668PMC
December 2017

Selecting immuno-oncology-based drug combinations - what should we be considering?

Expert Rev Clin Pharmacol 2018 Oct 8;11(10):971-985. Epub 2018 Sep 8.

a Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics , Istituto Nazionale Tumori IRCCS Fondazione G. Pascale , Napoli , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2018.1518713DOI Listing
October 2018

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.

J Clin Oncol 2018 10 15;36(28):2836-2844. Epub 2018 Aug 15.

Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.6212DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161834PMC
October 2018

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.

Authors:
Franck Pagès Bernhard Mlecnik Florence Marliot Gabriela Bindea Fang-Shu Ou Carlo Bifulco Alessandro Lugli Inti Zlobec Tilman T Rau Martin D Berger Iris D Nagtegaal Elisa Vink-Börger Arndt Hartmann Carol Geppert Julie Kolwelter Susanne Merkel Robert Grützmann Marc Van den Eynde Anne Jouret-Mourin Alex Kartheuser Daniel Léonard Christophe Remue Julia Y Wang Prashant Bavi Michael H A Roehrl Pamela S Ohashi Linh T Nguyen SeongJun Han Heather L MacGregor Sara Hafezi-Bakhtiari Bradly G Wouters Giuseppe V Masucci Emilia K Andersson Eva Zavadova Michal Vocka Jan Spacek Lubos Petruzelka Bohuslav Konopasek Pavel Dundr Helena Skalova Kristyna Nemejcova Gerardo Botti Fabiana Tatangelo Paolo Delrio Gennaro Ciliberto Michele Maio Luigi Laghi Fabio Grizzi Tessa Fredriksen Bénédicte Buttard Mihaela Angelova Angela Vasaturo Pauline Maby Sarah E Church Helen K Angell Lucie Lafontaine Daniela Bruni Carine El Sissy Nacilla Haicheur Amos Kirilovsky Anne Berger Christine Lagorce Jeffrey P Meyers Christopher Paustian Zipei Feng Carmen Ballesteros-Merino Jeroen Dijkstra Carlijn van de Water Shannon van Lent-van Vliet Nikki Knijn Ana-Maria Mușină Dragos-Viorel Scripcariu Boryana Popivanova Mingli Xu Tomonobu Fujita Shoichi Hazama Nobuaki Suzuki Hiroaki Nagano Kiyotaka Okuno Toshihiko Torigoe Noriyuki Sato Tomohisa Furuhata Ichiro Takemasa Kyogo Itoh Prabhu S Patel Hemangini H Vora Birva Shah Jayendrakumar B Patel Kruti N Rajvik Shashank J Pandya Shilin N Shukla Yili Wang Guanjun Zhang Yutaka Kawakami Francesco M Marincola Paolo A Ascierto Daniel J Sargent Bernard A Fox Jérôme Galon

Lancet 2018 05 10;391(10135):2128-2139. Epub 2018 May 10.

INSERM, Laboratory of Integrative Cancer Immunology, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Sorbonne Universités, Paris, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(18)30789-XDOI Listing
May 2018

The Great Debate at "Melanoma Bridge", Napoli, December 2nd, 2017.

J Transl Med 2018 04 17;16(1):101. Epub 2018 Apr 17.

Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

View Article

Download full-text PDF

Source
https://translational-medicine.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s12967-018-1477-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905181PMC
April 2018

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

N Engl J Med 2018 May 15;378(19):1789-1801. Epub 2018 Apr 15.

From the Gustave Roussy Cancer Campus Grand Paris and University Paris-Saclay, Villejuif (A.M.M.E., C.R.), Hospices Civils de Lyon Cancer Institute, Cancer Research Center of Lyon, Lyon University, Lyon (S.D.), and Aix-Marseille University, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille, Marseille (J.-J.G.) - all in France; Netherlands Cancer Institute-Antoni van Leeuwenhoek (C.U.B., A.C.J.A.) and VU University Medical Center (A.J.M.E.), Amsterdam, and Radboud University Medical Center Nijmegen, Nijmegen (R.K.) - all in the Netherlands; Azienda Ospedaliera Papa Giovanni XXIII, Bergamo (M. Mandala), Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico Fondazione G. Pascale, Naples (P.A.A.), and Universita Degli Studi Di Siena-Policlinico le Scotte, Siena (M. Maio) - all in Italy; Melanoma Institute Australia, the University of Sydney, and Mater and Royal North Shore Hospitals (G.V.L.) and Westmead and Blacktown Hospitals, Melanoma Institute Australia and the University of Sydney (M.S.C.), Sydney, Princess Alexandra Hospital, University of Queensland, Brisbane (V.A.), Alfred Hospital (A.H.) and Peter MacCallum Cancer Centre (S. Sandhu), Melbourne, VIC, and Fiona Stanley Hospital-University of Western Australia-Edith Cowan University Perth, Perth (A.K.) - all in Australia; Cancer Research Center, Moscow (M.L.); Royal Marsden Hospital, London (J.L.); Hospital Clinic Universitari de Barcelona, Barcelona (S.P.); Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); University Hospital Essen, Essen and German Cancer Consortium, Heidelberg (D.S.), and the Skin Cancer Center, Department of Dermatology, Hannover Medical School, Hannover (R.G.) - all in Germany; Washington University School of Medicine, St. Louis (L.H.-A.); Centre Hospitalier de l'Université de Montréal (CHUM), Centre de Recherche du CHUM, Montreal (R.J.); Christie NHS Foundation Trust, Manchester, United Kingdom (P.L.); Merck, Kenilworth, NJ (N.I.); and the European Organization for the Research and Treatment of Cancer Headquarters, Brussels (S.M., S. Suciu).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1802357DOI Listing
May 2018

The influence of diet on anti-cancer immune responsiveness.

J Transl Med 2018 03 20;16(1):75. Epub 2018 Mar 20.

Section of Clinical Nutrition and Nutrigenomics, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12967-018-1448-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859494PMC
March 2018

Genetic alterations in main candidate genes during melanoma progression.

Oncotarget 2018 Feb 3;9(9):8531-8541. Epub 2018 Jan 3.

Unit of Cancer Genetics, Institute of Biomolecular Chemistry, National Research Council, Sassari, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.23989DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823576PMC
February 2018

Adjuvant Therapy in Resected Melanoma.

N Engl J Med 2018 02;378(7):680

Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1716071DOI Listing
February 2018

Neoadjuvant therapy in melanoma: the next step?

Lancet Oncol 2018 02 18;19(2):151-153. Epub 2018 Jan 18.

Cancer Institute Gustave Roussy, University Paris-Sud, 98400 Villejuif/Paris-Sud, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30016-0DOI Listing
February 2018

What is changing in the adjuvant treatment of melanoma?

Oncotarget 2017 Dec 6;8(67):110735-110736. Epub 2017 Dec 6.

Paolo A. Ascierto: Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Napoli, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.22988DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762277PMC
December 2017